Craig, you know as well as anyone that “class me
Post# of 158771
(Total Views: 325)
Posted On: 12/01/2025 6:18:59 PM
Re: craigakess #158757
Craig, you know as well as anyone that “class member” doesn’t mean “meaningful shareholder.”
Most of the plaintiffs in this case held tiny positions — some under 300 shares — and were motivated by short-term frustration, not real losses or long-term alignment.
That’s why the settlement number is low, why no major funds joined it, and why most long-term shareholders chose not to participate.
Anyone who held CYDY through 2020 understood two things:
1. A class action actively harms the underlying asset.
2. Pursuing statutory/punitive damages against your own company rarely benefits shareholders or patients.
It’s easy for small positions to file a lawsuit.
It’s harder — and far more responsible — to think about patients, platform value, future indications, and long-range shareholder benefit.
The people who stayed the course weren’t “lied to” — they simply recognized that:
• the former CEO made serious mistakes
• the science remained intact
• the platform was bigger than one individual’s misconduct
• and litigation wasn’t the path to value creation
This settlement clears the deck and finally removes a drag on the company’s ability to move forward with oncology, mCRC, and mTNBC.
If anything, today’s 8-K confirms what long-term shareholders already understood:
stability, not lawsuits, is what actually protects value.
Most of the plaintiffs in this case held tiny positions — some under 300 shares — and were motivated by short-term frustration, not real losses or long-term alignment.
That’s why the settlement number is low, why no major funds joined it, and why most long-term shareholders chose not to participate.
Anyone who held CYDY through 2020 understood two things:
1. A class action actively harms the underlying asset.
2. Pursuing statutory/punitive damages against your own company rarely benefits shareholders or patients.
It’s easy for small positions to file a lawsuit.
It’s harder — and far more responsible — to think about patients, platform value, future indications, and long-range shareholder benefit.
The people who stayed the course weren’t “lied to” — they simply recognized that:
• the former CEO made serious mistakes
• the science remained intact
• the platform was bigger than one individual’s misconduct
• and litigation wasn’t the path to value creation
This settlement clears the deck and finally removes a drag on the company’s ability to move forward with oncology, mCRC, and mTNBC.
If anything, today’s 8-K confirms what long-term shareholders already understood:
stability, not lawsuits, is what actually protects value.
(11)
(0)